Celerion
and
BryanLGH Health System
, a locally owned, non-profit healthcare organization, announce an alliance to provide a dedicated wing at BryanLGH Medical Center West in Lincoln, Nebraska for early clinical studies including Phase I and First-In-Human.
This exclusive alliance will provide pharmaceutical, and biotechnology companies the opportunity to place clinical studies in a hospital environment, thus increasing safety for study volunteers and improving access to hospital procedures and techniques for studies placed at Celerion’s Lincoln clinical facility. Celerion will have access to 24 in-patient beds, in the newly launched Celerion-BryanLGH Clinical Research Unit. Celerion will leverage over forty years experience conducting clinical studies and will incorporate the same staff, global standard operating procedures and institutional review board, ensuring consistency across all studies executed at our sites.
“Improving safety for participants in clinical studies, while getting drugs to market faster, is critical to pharmaceutical companies”, said Philip Bach, Vice President, Clinical Research at Celerion. “This alliance will allow Celerion to conduct studies in a hospital environment, providing round-the-clock emergency care. Celerion will also strengthen their capabilities with access to state-of-the-art hospital techniques and equipment, such as chest X-rays, PET scans, and MRIs, for studies executed at our clinical facility in Lincoln, Nebraska.”
“We are very pleased to collaborate with Celerion on this venture. Celerion’s staff is among the best in the industry, with extensive experience and expertise – going back to its founding in Lincoln in 1933 as Harris Labs”, said Kimberly A. Russel, President and CEO at BryanLGH. “This alliance affirms a major commitment by BryanLGH Health System to clinical research and is a natural extension of our medical expertise. We will safely help get drugs to market faster, which will benefit everybody.”
BryanLGH is one of only 74 hospitals in the United States to have received both the
2010 Distinguished Hospital Award for Clinical Excellence™
and the
Patient Safety Excellent Award™
from HealthGrades®.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.